Base de dados : LILACS
Pesquisa : D08.811.913.696.620.682.725.500.500 [Categoria DeCS]
Referências encontradas : 34 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 34 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-654967
Autor: Giunta, Marina; Pucillo, Carlo.
Título: BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy
Fonte: Rev. bras. hematol. hemoter;34(5):323-324, 2012.
Idioma: en.
Descritores:
Leucemia/etiologia
Proteínas de Fusão bcr-abl
Antígenos HLA
Imunoterapia
Limites: Seres Humanos
Tipo de Publ: Comentário
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  2 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-741874
Autor: Asinari, Mariana Beatriz; Zeballos, Maximiliano; Alicia, Sturich; Ricchi, Brenda Nidia; Basquiera, Ana Lisa.
Título: A case of chronic myeloid leukemia with the m-bcr (p190) molecular rearrangement identifi ed during treatment
Fonte: Rev. bras. hematol. hemoter;37(1):55-57, Jan-Feb/2015.
Idioma: en.
Descritores: Rearranjo Gênico
Leucemia Mielogênica Crônica BCR-ABL Positiva
Proteínas de Fusão bcr-abl
Diabetes Mellitus
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  3 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-898930
Autor: Vieira-Mion, Ana Lucia; Pereira, Noemi Farah; Funke, Vaneuza Araujo Moreira; Pasquini, Ricardo.
Título: Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
Fonte: Rev. bras. hematol. hemoter;39(3):210-215, July-Sept. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Background Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood. Objective To evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase of chronic myeloid leukemia monitored by quantitative real time polymerase chain reaction. Methods Between October 2002 and October 2010, 3169 peripheral blood samples were collected from 1403 patients from 3 to 5 months, 6 to 11 months, 12 to 17 months, 18 to 23 months and ≥24 months after beginning imatinib treatment. Eighty-two patients had samples available and analyzed for all time intervals. BCR-ABL1 quantification was performed by quantitative real time polymerase chain reaction using the ABL1 gene as the control. Results of the BCR-ABL1 ratio as a percentage were reported by the international scale (IS) using the laboratory conversion factor (0.51). Results In the first interval, 80.8% of patients achieved the optimal response (BCR-ABL1 IS ≤ 10%). In the second period, 69.1% achieved optimal response (BCR-ABL1 IS ≤ 1%) and, between 12 and 17 months, 47.3% achieved major molecular response (BCR-ABL1 IS ≤ 0.1%). Conclusions The results of this retrospective study show that the response to imatinib treatment (400 mg/day) of Brazilian patients in the chronic phase of chronic myeloid leukemia is within the expected profile when compared to patients reported in international prospective randomized studies.
Descritores: Brasil
Leucemia Mielogênica Crônica BCR-ABL Positiva
Mesilato de Imatinib
-Proteínas Tirosina Quinases
Proteínas de Fusão bcr-abl
Reação em Cadeia da Polimerase em Tempo Real
Limites: Seres Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  4 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Chauffaille, Maria de Lourdes L. F
Velloso, Elvira Deolinda Rodrigues Pereira
Simöes, Belinda Pinto
Rego, Eduardo Magalhäes
Texto completo
Texto completo
Id: biblio-898954
Autor: Silva, Fernanda Borges da; Machado-Neto, João Agostinho; Koury, Luisa Corrêa de Araujo; Bertini, Virginia Helena Leira Lipoli; Ratis, Cristina Alonso; Chauffaille, Maria de Lourdes Lopes Ferrari; Velloso, Elvira Deolinda Rodrigues Pereira; Simões, Belinda Pinto; Rego, Eduardo Magalhães; Traina, Fabiola.
Título: Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations
Fonte: Rev. bras. hematol. hemoter;39(4):379-384, Oct.-Dec. 2017. ilus.
Idioma: en.
Descritores: Leucemia Mieloide Aguda
Proteínas de Fusão bcr-abl
Limites: Seres Humanos
Masculino
Feminino
Adulto
Idoso de 80 Anos ou mais
Tipo de Publ: Relatos de Casos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  5 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-681971
Autor: Reis, Samuel Roosevelt Campos dos; Quixada, Acy Telles de Souza; Nunes, Sammara Tavares; Cid, Danielle Maria Camelo; Souza, Jacqueline Holanda de; Costa, Clara Maria Bastos Eloy da; Silveira, Carolina Bizelli; Cid, David Antonio Camelo; Oliveira, Mariana Fatima Cabral de.
Título: Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
Fonte: Rev. bras. hematol. hemoter;35(3):174-179, jun. 2013. tab, graf.
Idioma: en.
Resumo: Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies. .
Descritores:
Piperazinas/uso terapêutico
Leucemia Mielogênica Crônica BCR-ABL Positiva
Leucemia Mieloide
Proteínas de Fusão bcr-abl
Resultado do Tratamento
Adesão à Medicação
Limites: Seres Humanos
Masculino
Feminino
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  6 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-797310
Autor: Amaru Calzada, Ariel; Masias, Jose; Ustarez, Eduardo; Choque, German; Peñaloza, Rosario; Mansilla, Silvia; Amaru, Ricardo.
Título: Frecuencia de transcritos BCR/ABL p210 en 272 pacientes con leucemia mieloide crónica (LMC) en Bolivia / Frequency of p210 BCR-ABL transcripts in 272 Bolivian patients with chronic myeloid leukemia (CML)
Fonte: Rev. méd. (La Paz);22(1):13-19, 2016. ilus.
Idioma: es.
Resumo: INTRODUCCIÓN: existen dos formas principales del gen de fusión BCR/ABL, que involucra al exón 2 del gen ABL y a diferentes exones del gen BCR; los transcritos b2a2 o b3a2 codifican a la proteína p210, mientras que, el transcrito e1a2 codifica a la proteína p190. En Bolivia, no existe información sobre la frecuencia de estas isoformas (BCR/ABL quimérico) en pacientes con leucemia mieloide crónica (LMC). Objetivo.- Determinar la frecuencia de co-expresión de los transcritos p210 en pacientes con LMC de Bolivia. MATERIAL Y MÉTODO: se estudió 272 pacientes diagnosticados con LMC, entre julio del 1999 a agosto del 2015. Se realizó pruebas de RT-PCR (reverse transcriptase polymerase chain reaction) en muestras de médula ósea y sangre periférica de pacientes adultos y pediátricos con diagnóstico de LMC, positivos para algún tipo de reordenamiento BCR/ABL. RESULTADOS: la expresión del transcrito b2a2 se encontró en 96 pacientes (35,3%), el trascrito b3a2 en 154 casos (56,6%) y ambos transcritos en 22 pacientes (8,1%). Se realizó análisis de supervivencia, donde se observó que a los 5 años la tasa de sobrevida fue 64%; y la sobrevida libre de progresión 42%. También se observó que el tipo de transcrito no influye en la sobrevida total ni en la sobrevida libre de enfermedad. CONCLUSIÓN: se evidenció que no existen diferencias significativas de la expresión de los diferentes transcritos BCR/ABL de los pacientes estudiados en relación a otros estudios reportados.

There are two main forms of BCR/ABL fusion gene, involving exon 2 of ABL gene and different exons of the BCR gene, the transcripts b2a2 or b3a2 code for a p210 protein, and the transcript e1a2 code a p190 protein. In Bolivia, there is no information about the frequency of these isoforms of chimeric gene BCR/ABL in chronic myeloid leukemia (CML). The present study was designed to determine the frequency of co-expression of p210 transcripts in 272 patients with CML. It was conducted reverse transcriptase polymerase chain reaction (RT-PCR) tests in samples of bone marrow and peripheral blood of adult and pediatric patients with CML diagnosis, positive for some kind of BCR/ABL rearrangement. The transcript b2a2 was found in 96 (35,3%) patients; and b3a2 transcript in 154 (56.6%) cases; whereas, in 22 (8.1%) patients both transcripts were detected. Survival analysis was performed, it was observed that to 5 years the overall survival (OS) was 64%, and the progression free survival (PFS) was 42%. It was also observed that the type of transcript does not affect OS and PFS. Statistical analysis of our study, displayed no significant differences in the expression of different transcripts BCR/ABL of the Bolivian population, in relation to studies reported in other populations.
Descritores: Leucemia Mielogênica Crônica BCR-ABL Positiva
Proteínas de Fusão bcr-abl
Responsável: BO138.1 - Biblioteca Central


  7 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-753967
Autor: Ribeiro, Beatriz Felicio; Miranda, Eliana C.M.; Albuquerque, Dulcinéia Martins de; Delamain, Márcia T.; Oliveira-Duarte, Gislaine; Almeida, Maria Helena; Vergílio, Bruna; Silveira, Rosana Antunes da; Oliveira-Duarte, Vagner; Lorand-Metze, Irene; Souza, Carmino A. De; Pagnano, Katia B.B..
Título: Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
Fonte: Clinics;70(8):550-555, 08/2015. tab, graf.
Idioma: en.
Resumo: OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. METHODS: Bone marrow karyotyping and real-time quantitative polymerase chain reaction were performed at baseline and at 3, 6, 12 and 18 months after the initiation of treatment with a third tyrosine kinase inhibitor. Hematologic, cytogenetic and molecular responses were defined according to the European LeukemiaNet recommendations. BCR-ABL1 mutations were analyzed by Sanger sequencing. RESULTS: We evaluated 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase inhibitor. Nine patients were switched to dasatinib, and 16 patients were switched to nilotinib as a third-line therapy. Of the chronic phase patients (n=18), 89% achieved a complete hematologic response, 13% achieved a complete cytogenetic response and 24% achieved a major molecular response. The following BCR-ABL1 mutations were detected in 6/14 (43%) chronic phase patients: E255V, Y253H, M244V, F317L (2) and F359V. M351T mutation was found in one patient in the accelerated phase of the disease. The five-year overall, progression-free and event-free survivals were 86, 54 and 22% (p<0.0001), respectively, for chronic phase patients and 66%, 66% and 0% (p<0.0001), respectively, for accelerated phase patients. All blast crisis patients died within 6 months of treatment. Fifty-six percent of the chronic phase patients lost their hematologic response within a median of 23 months. CONCLUSIONS: Although the responses achieved by the third tyrosine kinase inhibitor were not sustainable, a third tyrosine kinase inhibitor may be an option for improving patient status until a donor becomes available for transplant. Because the long-term outcome ...
Descritores: Antineoplásicos/uso terapêutico
Dasatinibe/uso terapêutico
Resistência a Medicamentos/efeitos dos fármacos
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Inibidores de Proteínas Quinases/uso terapêutico
Proteínas Tirosina Quinases/antagonistas & inibidores
Pirimidinas/uso terapêutico
-Exame de Medula Óssea
Intervalo Livre de Doença
Proteínas de Fusão bcr-abl/genética
Estimativa de Kaplan-Meier
Cariotipagem
Leucemia Mielogênica Crônica BCR-ABL Positiva/genética
Mutação
Reação em Cadeia da Polimerase em Tempo Real
Fatores de Tempo
Resultado do Tratamento
Limites: Adolescente
Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Adulto Jovem
Tipo de Publ: Estudos de Avaliação
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  8 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-727664
Autor: Xia, D.Y.; Liu, L.; Hao, M.W.; Liu, Q.; Chen, R.A.; Liang, Y.M..
Título: A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;47(12):1096-1101, 12/2014. graf.
Idioma: en.
Resumo: p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore, we examined the effects of overexpressed p15INK4B on proliferation and apoptosis of CML cells. Overexpression of p15INK4B inhibited the growth of K562 cells by downregulation of cyclin-dependent kinase 4 (CDK4) and cyclin D1 expression. Overexpression of p15INK4B also induced apoptosis of K562 cells by upregulating Bax expression and downregulating Bcl-2 expression. Overexpression of p15INK4B together with STI571 (imatinib) or BCR-ABL1 small interfering RNA (siRNA) also enhanced growth inhibition and apoptosis induction of K562 cells. The enhanced effect was also mediated by reduction of cyclin D1 and CDK4 and regulation of Bax and Bcl-2. In conclusion, our study may provide new insights into the role of p15INK4B in CML and a potential therapeutic target for overcoming tyrosine kinase inhibitor resistance in CML.
Descritores: Apoptose/efeitos dos fármacos
Benzamidas/farmacologia
Proliferação Celular/efeitos dos fármacos
/metabolismo
CYCLIN-DEPENDENT KINASE INHIBITOR PABNORMALITIES, DRUG-INDUCED/metabolismo
Proteínas de Fusão bcr-abl/metabolismo
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Piperazinas/farmacologia
Pirimidinas/farmacologia
RNA Interferente Pequeno/farmacologia
-Antineoplásicos/farmacologia
Benzamidas/metabolismo
Ciclina D1/efeitos dos fármacos
Ciclina D1/metabolismo
/efeitos dos fármacos
CYCLIN-DEPENDENT KINASE ABBREVIATIONS AS TOPIC/efeitos dos fármacos
/metabolismo
CYCLIN-DEPENDENT KINASE ABBREVIATIONS AS TOPIC/metabolismo
/genética
CYCLIN-DEPENDENT KINASE INHIBITOR PABNORMALITIES, DRUG-INDUCED/genética
Combinação de Medicamentos
Resistência a Medicamentos Antineoplásicos
Regulação para Baixo/efeitos dos fármacos
Proteínas de Fusão bcr-abl/antagonistas & inibidores
Proteínas de Fusão bcr-abl/genética
Expressão Gênica/genética
KAMDINOCILLIN PIVOXIL CELLS
Leucemia Mielogênica Crônica BCR-ABL Positiva/metabolismo
Piperazinas/metabolismo
Inibidores de Proteínas Quinases/farmacologia
/efeitos dos fármacos
PROTO-ONCOGENE PROTEINS C-BCL-TEMEFOS/efeitos dos fármacos
/metabolismo
PROTO-ONCOGENE PROTEINS C-BCL-TEMEFOS/metabolismo
Pirimidinas/metabolismo
/efeitos dos fármacos
BCL-TEMEFOS-ASSOCIATED X PROTEIN/efeitos dos fármacos
Limites: Seres Humanos
Responsável: BR1.1 - BIREME


  9 / 34 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-725683
Autor: Azevedo, Ilana de França; Silva Júnior, Rui Milton Patrício da; Vasconcelos, Audrey Violeta Martins de; Neves, Washington Batista das; Melo, Fárida Coeli de Barros Correia; Melo, Raul Antônio Morais.
Título: Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
Fonte: Rev. bras. hematol. hemoter;36(5):351-355, Sep-Oct/2014. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco.
Resumo: Objective: This study investigated the occurrence of the p190 and p210 break point clusterregion-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and possible associations with clinical and laboratory characteristics and survival. Methods: Forty-one over 18-year-old patients with acute lymphoblastic leukemia of both genders followed-up between January 2008 and May 2012 were included in this study. Clinical and laboratory data were obtained from the medical charts of the patients. Reverse transcription polymerase chain reaction (RT-PCR) using specific primers was employed to identify molecular rearrangements. Results: At diagnosis, the median age was 33 years, and there was a predominance of males (61%). The most common immunophenotype was B lineage (76%). BCR-ABL rearrangements was detected in 14 (34%) patients with the following distribution: p190 (28%), p210 (50%) and double positive (22%). Overall survival of patients with a mean/median of 331/246 days of follow up was 39%, respectively, negative BCR-ABL (44%) and positive BCR-ABL (28%). Conclusion: These results confirm the high frequency of BCR-ABL rearrangements and the low survival rate of adult Brazilian patients with acute lymphoblastic leukemia...
Descritores: Adulto
Proteínas de Fusão bcr-abl
Leucemia Aguda Bifenotípica
Análise de Sobrevida
Limites: Seres Humanos
Adulto
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  10 / 34 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-703702
Autor: Almeida, Maria Helena de; Fogliatto, Laura; Couto, Dulce.
Título: Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
Fonte: Rev. bras. hematol. hemoter;36(1):54-59, Jan-Feb/2014.
Idioma: en.
Resumo: Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.
Descritores: Proteínas de Fusão bcr-abl
Leucemia Mielogênica Crônica BCR-ABL Positiva
Proteínas Tirosina Quinases
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde